Systemic sclerosis
199 results
101 - 199
Alemtuzumab for multiple sclerosis
Diseases of the spinal cord - Cyclophosphamide for multiple sclerosis
- Natalizumab for multiple sclerosis
- Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis
- Raynaud's phenomenon (RP) or white finger disease
Reflexology of uncertain clinical benefit- Corticosteroids or ACTH for acute exacerbations in multiple sclerosis
- Statins for multiple sclerosis: Cochrane systematic review
- Sodium channel blockers for neuroprotection in multiple sclerosis
- alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis
- Respiratory muscle training for multiple sclerosis
- Exercise therapy for fatigue in multiple sclerosis
- Virtual reality for multiple sclerosis rehabilitation
- Vitamin D for the management of multiple sclerosis
- Laquinimod for multiple sclerosis
- Intravenous immunoglobulins for multiple sclerosis
- Peripheral neuropathies: examination of the patient
- Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis
- Neuropsychological rehabilitation for multiple sclerosis: Cochrane systematic review
- Rituximab for people with multiple sclerosis
- Occupational therapy for multiple sclerosis
- Pharmacological treatment for memory disorder in multiple sclerosis: Cochrane systematic review
- Non pharmacological interventions for spasticity in multiple sclerosis
- Effectiveness of vocational rehabilitation intervention on the return to work and employment of persons with multiple sclerosis
- Multiple sclerosis (MS)
- Glatiramer acetate for multiple sclerosis
- Cyclophosphamide for connective tissue disease–associated interstitial lung disease
- Phosphodiesterase 5 inhibitors for Raynaud's phenomenon
- Ataxia
- Cladribine for people with multiple sclerosis
- Azathioprine for people with multiple sclerosis
- Daclizumab for relapsing remitting multiple sclerosis
- Telerehabilitation for persons with multiple sclerosis
- Glatiramer acetate for multiple sclerosis
- Immunomodulators and immunosuppressants for multiple sclerosis: a network meta‐analysis
- Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon
- Idiopathic sudden sensorineural hearing loss
- Hiccup
- Probiotics for preventing urinary tract infection in people with neuropathic bladder
- Whole-body vibration training for patients with neurodegenerative disease: Cochrane systematic review
- Non‐pharmacological interventions for chronic pain in multiple sclerosis
- Palliative care interventions for people with multiple sclerosis
- Rituximab for relapsing-remitting multiple sclerosis: Cochrane systematic review
- Dysphagia
- Information provision for people with multiple sclerosis
- Natalizumab for relapsing remitting multiple sclerosis
- Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in people with multiple sclerosis
- Fingolimod for relapsing‐remitting multiple sclerosis
- Contraception in patients with systemic diseases
- Interventions for preventing falls in people with multiple sclerosis
- Dietary interventions for multiple sclerosis‐related outcomes
- Botulinum toxin effective for excessive drooling
- Chronic pain
- Dimethyl fumarate for multiple sclerosis: Cochrane systematic review
- Primary Sjögren's syndrome
- Teriflunomide for multiple sclerosis
- Myositis
- Muscle weakness and paralysis symptom
- Treatment with disease‐modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
- Siponimod for multiple sclerosis
- Cyclophosphomide reduces dyspnea in scleroderma lung disease
- Temperature-induced skin disorders
- Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis
- Hyperbaric oxygen therapy (HBOT)
- Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction
- Rapamycin and rapalogs for tuberous sclerosis complex
- Pruritus
- Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain‐Barré syndrome
- Transient ischaemic attack (TIA)
- Corticosteroids for treating optic neuritis
- Herbal medicinal products or preparations for neuropathic pain
- Calcium channel blockers for primary and secondary Raynaud's phenomenon
- Conservative, physical and surgical interventions for managing faecal incontinence and constipation in adults with central neurological diseases
- Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic obstruction
- Lyme borreliosis (LB)
- Injection sclerotherapy for varicose veins
- Trigeminal neuralgia and other facial pain